The European Federation of Pharmaceutical Industries and Associations (EFPIA), in collaboration with the EFPIA Oncology Platform (EOP), commissioned a report by Charles River Associates (CRA) to highlight the role of precision health (PH) and precision medicine (PM) in addressing population health needs and the benefits they deliver to European health systems.
The benefits of precision medicine (PM) are becoming increasingly evident in treating conditions like cancer and genetic disease. However, a new report highlights the growing body of evidence for the use of precision health (PH) approaches in supporting disease prevention and patient management.
PM refers to the use of molecular information, such as genomics, along with phenotypic and health data from patients, to generate care insights to prevent or treat disease. This can improve health outcomes by tailoring treatment to individual patients.
PH is a broader concept that goes beyond the provision of care. This approach uses population-specific data to provide the right intervention to the right population at the right time. PH can be applied to common chronic conditions, such as diabetes and cardiovascular disease, as well as cancer and infectious diseases such as COVID-19.